Compound Metformin Hydrochloride Tablets, a new kind of medicine, is II type medicine for diabetes. The features of this medicine are: the two components of the preparation itself are the most widely used peroral hypoglycemic agent at present, and along with diet and exercise, it was approved by U.S.A FDA in 2000 as the initial medicine of II type medicine for diabetes and it was also approved to be used for the treatment that took sulfonylurea medicine as well as had diet and exercise treatment at one time. For the diabetics whose blood sugar level is not controlled properly yet, taking both of the two components can improve II type diabetics’ blood sugar. It is claimed that the medicine represents a new treatment for type II diabetes, which is expected to change the treatment case for diabetics. It is proven by the clinical trials that compared with two simple recipe preparations, this product has stronger hypoglycemic function.

　　Statistics by State Ministry of Health that the total number of diagnosed diabetics in our country is over 40 million while 70 million “Impaired Glucose Tolerance” group of potential diabetics. With the living standard increasingly enhanced, the attack rate of diabetes is increasing as well. Our country is facing the threat of the outbreak of diabetes and the attack rate will break through 10%. Followed cardiovascular diseases and cancer, diabetes now is the third killer to human beings. In year 2001, the market sale of diabetes medicine was about RMB6 billion with stable upward trend and the annual average growth rate is above 25%. Since this product has more visible curative effect when compared with the simple compound metformin hydrochloride tablets and glibenclamide tablets sold on the market and can be accepted by diabetics with medium-low price, it is easy to occupy certain market share. It is predicted that within 2-3 years, the product can occupy the market share of RMB2 billion. It is reported that there are only 7-8 domestic pharmaceutical factories authorized to register for the new medicine, so the competitive power is correspondingly small. The potential adversary is repaglinide. However, the price of repaglinide is higher, which cannot be accepted by quite a number of diabetics. After put into production, the scale of this medicine will be 100 million tablets per year. Calculating the sales amount by 80% of the production scale that occupies 2% market share, it is predicted that the sales amount can reach RMB40 million, and the profit will be RMB8 million counted by profit margin of 20%.